Joshua Fitch, Senior Editor

Following the FDA's acceptance of the NDA, a PDUFA date of December 26, 2024 has been set for setmelanotide in patients as young as 2 years of age.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A CDC report reviews HPV vaccination trends in US Pacific Islands, revealing mixed progress towards the 2030 goal of 90% completion among girls by age 15.

The federal agency advised manufacturers in June that 2024-2025 COVID-19 vaccines should be monovalent JN.1, with the preferred lineage being the KP.2 strain.

Healthcare providers should maintain heightened suspicion of parvovirus B19 in individuals presenting with symptoms, particularly those at high risk.

Lynn Malec, MD, joins Contemporary Pediatrics once again for a discussion of the hemophilia A space and how pediatric health care providers fit into care.

Expert discussion of several topics including diagnosis, clinical management in older adults, multidrug resistance, and long-acting injectables and PrEP.

The FDA approved anacaulase-bcdb for pediatric use, allowing its application for eschar removal in deep thermal burns for ages newborn to 18 years.

The USPSTF statement aligns with the 2015 recommendation on insufficient evidence for pregnancy iron deficiency screening or supplementation.

Findings show that that feeding mode is by far the most defining factor for microbial composition," wrote the study authors.

A JAMA Pediatrics study found 37% of adolescents with gender dysphoria began hormone therapy within 2 years, highlighting barriers and inequities in care.

An interactive text message program boosted vaping cessation rates by 35% among adolescents compared to a control group, a JAMA study found.

The approval is indicated for adult and pediatric patients who weigh at least 88 lbs (40 kg).

Among children born in 2020, vaccination coverage was 4 to 14 percentage points lower among those who were eligible for VFC versus non-eligible children.

How can tablet use contribute to expressions of anger and frustration among children aged 3.5 to 5.5 years?

Findings suggest outdoor interventions should focus on effective outdoor exposure patters to prevent myopia in children.

Lynn Malec, MD, joined us to discuss the phase 3 XTEND-Kids study of ALTUVIIIO in pediatric patients with hemophilia A.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The approval is indicated for adult and pediatric patients who weight at least 66 pounds (30 kilograms).

Digital tools like health apps, texts, and telemedicine show promise in managing childhood obesity, but require sustained engagement for long-term impact.

Digital therapeutics help kids build emotional regulation and coping skills, supporting pediatric care while waiting for specialized mental health services.

Suicide was among the top 9 leading causes of death for people aged 10 to 64 years, and was the second leading cause of death for individuals aged 10 to 14 years and 25 to 34 years in 2022.

Current treatment is primarily supportive care consisting of increased fluid intake to dilute oxalate in the urine, along with pyridoxine, or vitamin B6, to reduce oxalate production.

The formula company issued a recall of the products on May 24, 2024, though they were not in compliance with all of the FDA’s infant formula regulations.

A pair of medical directors involved in the transplant clinical space provide commentary on heart and lung transplants in the pediatric population.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Using school-based approaches and staying in close contact with school personnel can increase overall care for the child.

Nine of 32 (28.1%) patients in the mitapivat arm achieved a transfusion reduction response compared to 11.8% of patients in the placebo arm.

Diamyd to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2 was granted Fast Track designation by the FDA in February 2024.

Erica Prochaska, MD, highlights a recent study that aimed to estimate the rate of HOB among infants admitted to the NICU, measure the association of HOB risk with birth weight group and postnatal age, and estimate HOB-attributable mortality.